Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vasopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 7/20 | 1.00 |
| ▸ | AVPR1B known ✓ | P47901 | 5/20 | 1.00 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 1.00 |
| ▸ | OXTR | P30559 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vasopressin SCHEMBL19712236 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL18937546 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL17874853 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.98 | AVPR1A (0.97) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL23879427 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL18476287 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL24390785 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL19733909 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL1172390 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL29500557 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3655036-B1 | COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS | HOFFMAN TECH LLC (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4313106-B1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024142211-A1 | THERAPEUTIC AGENT FOR DEMENTIA | 今村 純一 | 2024-07-04 | — | — | WO | disclosed |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-1831382-B1 | METHOD FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS | HOLM PER SONNE (AT) | 2023-01-18 | — | — | EP | disclosed |
| US-20220339219-A1 | METHOD FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS | HOLM PER SONNE (DE) | 2022-10-27 | — | — | US | disclosed |
| WO-2022200568-A1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2022-09-29 | — | — | WO | disclosed |
| US-11369650-B2 | Methods for reversing multiple resistance in animal cells | HOLM PER SONNE (DE) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339219-A1 | METHOD FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS | SLC11A2, HAVCR2, VIM | AVPR1A 1535/4885AVPR1B 1472/4885AVPR2 1732/4885 |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | OXTR, GRPR, NTSR2 | AVPR1A 22/4885AVPR1B 21/4885AVPR2 14/4885 |
| US-11369650-B2 | Methods for reversing multiple resistance in animal cells | SLC11A2, HAVCR2, CD44 | AVPR1A 1900/4885AVPR1B 1718/4885AVPR2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.